ArticleAmerican journal of human genetics1998
Prenatal screening for cystic fibrosis carriers: an economic evaluation.
Article in American journal of human genetics, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 4 syntheses or guidelines pooled it, 71 citations in OpenAlex.
- How are maternal and fetal outcomes incorporated when measuring benefits of interventions in pregnancy? Findings from a systematic review of cost-utility analyses.Health and quality of life outcomes · 2024Pooled it
- A Systematic Review of Methods and Practice for Integrating Maternal, Fetal, and Child Health Outcomes, and Family Spillover Effects into Cost-Utility Analyses.PharmacoEconomics · 2024Pooled it
- A Systematic Review of Methods Used by Pediatric Cost-Utility Analyses to Include Family Spillover Effects.PharmacoEconomics · 2024Pooled it
- Carrier Screening Programs for Cystic Fibrosis, Fragile X Syndrome, Hemoglobinopathies and Thalassemia, and Spinal Muscular Atrophy: A Health Technology Assessment.Ontario health technology assessment series · 2023Pooled it
- Impact of pulmonary exacerbations and lung function on generic health-related quality of life in patients with cystic fibrosis.Health and quality of life outcomes · 2016Trial
- Cost-effectiveness of the CFTR gene-sequencing test for asymptomatic carriers in the Colombian populationBiomedica : revista del Instituto Nacional de Salud · 2020Article
- Non-invasive prenatal sequencing for multiple Mendelian monogenic disorders using circulating cell-free fetal DNA.Nature medicine · 2019Article
- Carrier screening by next-generation sequencing: health benefits and cost effectiveness.Molecular genetics & genomic medicine · 2016Article
- Evaluating Cost-effectiveness of Interventions That Affect Fertility and Childbearing: How Health Effects Are Measured Matters.Medical decision making : an international journal of the Society for Medical Decision Making · 2015Review
- Impact of gene patents and licensing practices on access to genetic testing for cystic fibrosis.Genetics in medicine : official journal of the American College of Medical Genetics · 2010Article
- Measuring the value of public health systems: the disconnect between health economists and public health practitioners.American journal of public health · 2008Article
- Measuring health preferences for use in cost-utility and cost-benefit analyses of interventions in children: theoretical and methodological considerations.PharmacoEconomics · 2007Review
- Cost-effectiveness of a school-based Tay-Sachs and cystic fibrosis genetic carrier screening program.Genetics in medicine : official journal of the American College of Medical Genetics · 2005Article
- Attitudes of potential providers towards preconceptional cystic fibrosis carrier screening.Journal of genetic counseling · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
The cloning of the CFTR gene has made it technically possible to avert the unwanted birth of a child with cystic fibrosis (CF). Several large trials offering prenatal CF carrier screening suggest that such screening is practical and that identified carriers generally use the information obtained. Therefore, a critical question is whether the cost of such screening is justified. Decision analysis was performed that used information about choices that pregnant women were observed to make at each stage in the Rochester prenatal carrier-screening trial. The cost of screening per CF birth voluntarily averted was estimated to be $1,320,000-$1,400,000. However, the lifetime medical cost of the care of a CF child in today's dollars was estimated to be slightly>$1,000,000. Therefore, despite both the high cost of carrier testing and the relative infrequency of CF conceptions in the general population, the averted medical-care cost resulting from choices freely made are estimated to offset approximately 74%-78% of the costs of a screening program. At present, if it is assumed that a pregnancy terminated because of CF is replaced, the marginal cost for prenatal CF carrier screening is estimated to be $8,290 per quality-adjusted life-year. This value compares favorably with that of many accepted medical services. The cost of prenatal CF carrier screening could fall to equal the averted costs of CF patient care if the cost of carrier testing were to fall to $100.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.